艾滋病抗病毒治疗新药绥美凯怎么样

On January 22, 2018, GlaxoSmithKline (GSK) announced that its new drug for the treatment of HIV (generic name: dolutegravir tablets) was officially launched in mainland China. This is a single-pill compound preparation with the new generation integrase inhibitor dolutegravir (DTG) as the core. It is also the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. After a new drug is launched, the first thing patients pay attention to is definitely the therapeutic effect of the drug. What about the new HIV antiviral drug Suimeikai?

Trimax uses DTG (dolutegravir) integrase inhibitor as its core. In clinical trials, DTG had a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which were 5.8% and 0.5% respectively. In the SINGLE trial, the 48-week primary analysis showed that the proportion of patients who achieved virological suppression was better in the dolutegravir XxXABC/3TC group than in the FTC/TDF/ETC group (p=0.003). It can be seen that Suimeike has obvious viral suppression effect and low incidence of side effects, making it a good choice for HIV patients.

The launch of Suimeike in my country provides a new treatment option for domestic HIV patients. In clinical trials, Suimeike has a significantly higher virus-inhibiting effect, has fewer side effects, and rarely leads to discontinuation of treatment. Moreover, Suimeikai is an oral tablet and does not need to consider food factors. It is easy to use, reducing the patient's medication burden and improving the patient's compliance. In terms of drug resistance, Suimeikan is not prone to drug resistance, and patients can use it for a long time.

The above is an introduction to the effects of new drugs in treating AIDS patients. Patients must carefully follow the doctor's instructions during treatment in order to have more effective effects of the drugs, and do not use drugs blindly.

Recommended related hot articles: /newsDetail/80770.html